🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Nasopharyngeal Carcinoma

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC) NCT06829147n/a1 site📍 Guangzhou Sun Yat-sen University TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC NCT07325539Phase 22 sites📍 Guangzhou📍 Shenzhen Sun Yat-sen University · Tests: Gemcitabine(GEM), Cisplatin, Toripalimab, LDRT Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Camrelizumab, Gemcitabine, Cisplatin, Apatinib Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer NCT03010150n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Biospecimen Collection, Questionnaire Administration Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial NCT07070479Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ming-Yuan Chen · Tests: Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) NCT06064097Phase 286 sites📍 Birmingham📍 Phoenix📍 Little Rock National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial NCT07101744Phase 21 site📍 Guangdong Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab Individualized Elective Neck Irradiation in NPC Patients NCT06241612Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Individualized Elective Neck Irradiation Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423Phase 11 site📍 Chengdu West China Hospital · Tests: EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska LDRT and Chemoimmunotherapy in NPC With Liver Metastasis NCT06788002Phase 28 sites📍 Changsha📍 Changsha📍 Changsha Hunan Cancer Hospital · Tests: Low-dose radiotherapy combine with chemoimmunotherapy Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma NCT06509009Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nimotuzumab Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC NCT06177301Phase 31 site📍 Shanghai Fudan University · Tests: Tislelizumab combined with GX, Tislelizumab combined with GP Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation NCT06662058NA1 site📍 Atlanta Emory University · Tests: Audiometric Test, Audiometric Test, Audiometric Test, Interview [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers NCT06479811Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. NCT06383780Phase 31 site📍 Guangzhou XIANG YANQUN · Tests: GP combined with Tislelizumab, TPC combined with Tislelizumab A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT06475300Phase 21 site📍 Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC NCT04544969n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemotherapy SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: SBRT combined with Nimotuzumab followed by Tislelizumab Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites📍 Nashville📍 Nashville📍 Nashville Vanderbilt University Medical Center · Tests: biologic sample preservation procedure, medical chart review Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270Phase 295 sites📍 Dublin📍 Fremont📍 Fresno National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. NCT07258979Phase 1, Phase 220 sites📍 Chongqing📍 Fuzhou📍 Xiamen MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL201, Toripalimab, Cisplatin JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma NCT07690787Phase 21 site📍 Hong Kong Chinese University of Hong Kong · Tests: JS207, Paclitaxel, Capecitabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy